IntelGenx Announces Listing Reaching Halfway Through

SAINT LAURENT, Quebec, Sept. 08, 2022 (GLOBE NEWSWIRE) — IntelGenx Corp. (TSX: IGX) (OTCQB: IGXT) (the “Company” or “IntelGenx”) today announced that patient enrollment in Montelukast VersaFilm is underway® The Phase 2a (“BUENA”) clinical trial in patients with mild to moderate Alzheimer’s disease (“AD”) is halfway through.

This proof-of-concept study currently includes six clinical research sites with the possibility of adding two more in the coming month, all of which are expected to enroll approximately 70 patients in total.

“We are encouraged by the speed with which AD patients are enrolling in this trial following the resumption of our recruitment efforts,” said Dr. Horst Zerbe, CEO of IntelGenx. “We continue to work diligently to further improve the recruitment rate and expect to complete enrollment before the end of 2022.”

About Montelukast VersaFilm®

Montelukast is a leukotriene receptor antagonist that was approved by the United States Food and Drug Administration in 1997 for the treatment of asthma and seasonal allergic rhinitis. IntelGenx is working to reuse Montelukast as a therapeutic agent to treat neurodegenerative diseases by reformulating the drug into an oral film product. IntelGenx proprietary VersaFilm® is particularly suitable for patient populations with special needs, and Montelukast VersaFilm® The product offers many distinct advantages over tablets for patients with Alzheimer’s disease, including avoidance and minimization of first-pass effects, ease of administration, improved bioavailability of API, reduction in dosage and toxicity, better acceptability and better compliance.

In Phase 1 studies, IntelGenx demonstrated that an oral film formulation of Montelukast is safe and tolerable in healthy subjects, reduces first-pass effect, and has 52% higher bioavailability compared to the Montelukast tablet. Ordinary Montelukast, showing a clear benefit to administering Montelukast. through cinema. IntelGenx Oral Film also crossed the blood-brain barrier, a critical feature for the treatment of degenerative brain diseases.

About IntelGenx

IntelGenx is a leading drug delivery company specializing in the development and manufacturing of pharmaceutical films.

IntelGenx’s superior film technologies, including VersaFilm®DisinteQVetaFilm and transdermal VevaDerm, enable next-generation pharmaceuticals that address unmet medical needs. IntelGenx’s pipeline of innovative products provides significant benefits to patients and physicians for numerous therapeutic conditions.

IntelGenx’s highly skilled team provides comprehensive pharmaceutical services to pharma partners, including R&D, analytical method development, clinical oversight, intellectual property, and regulatory services. IntelGenx’s state-of-the-art manufacturing facility offers full service by providing lab-scale, pilot-scale, and commercial-scale production. For more information, visit www.intelgenx.com.

Forward-looking information and statements

This document may contain forward-looking information about IntelGenx’s operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx’s plans, goals, expectations, strategies, intentions, or other characterizations of future events or circumstances and are generally identified by the words “may”, “s ‘expects’, ‘anticipates’, ‘intends’, ‘projects’, ‘believes’, ‘seeks’, ‘estimates’, ‘could’, ‘would’ and similar expressions. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx’s actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under “Risk Factors” in IntelGenx’s Annual Report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www. sec.gov, and also filed with the Canadian securities regulators at www.sedar.com. IntelGenx undertakes no obligation to update these forward-looking statements.

Source: Intel Genx Technologies Corp.

For Intel Genx:

Stephen Kilmer
Investor Relations
(647) 872-4849
[email protected]

Or

André Godin, CPA, CA
President and Chief Financial Officer
IntelGenx Corp.
(514) 331-7440 ext. 203
[email protected]

Comments are closed.